JP6339998B2 - 幹細胞よりナチュラルキラー細胞を発生させる方法 - Google Patents

幹細胞よりナチュラルキラー細胞を発生させる方法 Download PDF

Info

Publication number
JP6339998B2
JP6339998B2 JP2015509079A JP2015509079A JP6339998B2 JP 6339998 B2 JP6339998 B2 JP 6339998B2 JP 2015509079 A JP2015509079 A JP 2015509079A JP 2015509079 A JP2015509079 A JP 2015509079A JP 6339998 B2 JP6339998 B2 JP 6339998B2
Authority
JP
Japan
Prior art keywords
cells
cell
natural killer
serum
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015509079A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015519890A (ja
JP2015519890A5 (OSRAM
Inventor
ダン エス． カウフマン，
ダン エス． カウフマン，
デイビッド エー． クノール，
デイビッド エー． クノール，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2015519890A publication Critical patent/JP2015519890A/ja
Publication of JP2015519890A5 publication Critical patent/JP2015519890A5/ja
Application granted granted Critical
Publication of JP6339998B2 publication Critical patent/JP6339998B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2303—Interleukin-3 (IL-3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1171—Haematopoietic stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2527/00—Culture process characterised by the use of mechanical forces, e.g. strain, vibration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2015509079A 2012-04-24 2013-04-23 幹細胞よりナチュラルキラー細胞を発生させる方法 Active JP6339998B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261637592P 2012-04-24 2012-04-24
US61/637,592 2012-04-24
PCT/US2013/037782 WO2013163171A1 (en) 2012-04-24 2013-04-23 Method for developing natural killer cells from stem cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017115944A Division JP6529541B2 (ja) 2012-04-24 2017-06-13 幹細胞よりナチュラルキラー細胞を発生させる方法

Publications (3)

Publication Number Publication Date
JP2015519890A JP2015519890A (ja) 2015-07-16
JP2015519890A5 JP2015519890A5 (OSRAM) 2016-06-23
JP6339998B2 true JP6339998B2 (ja) 2018-06-06

Family

ID=48289670

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015509079A Active JP6339998B2 (ja) 2012-04-24 2013-04-23 幹細胞よりナチュラルキラー細胞を発生させる方法
JP2017115944A Active JP6529541B2 (ja) 2012-04-24 2017-06-13 幹細胞よりナチュラルキラー細胞を発生させる方法
JP2019091121A Pending JP2019122415A (ja) 2012-04-24 2019-05-14 幹細胞よりナチュラルキラー細胞を発生させる方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017115944A Active JP6529541B2 (ja) 2012-04-24 2017-06-13 幹細胞よりナチュラルキラー細胞を発生させる方法
JP2019091121A Pending JP2019122415A (ja) 2012-04-24 2019-05-14 幹細胞よりナチュラルキラー細胞を発生させる方法

Country Status (5)

Country Link
US (1) US9260696B2 (OSRAM)
EP (2) EP3567102A1 (OSRAM)
JP (3) JP6339998B2 (OSRAM)
AU (3) AU2013251785B2 (OSRAM)
WO (1) WO2013163171A1 (OSRAM)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9260696B2 (en) * 2012-04-24 2016-02-16 Dan S. Kaufman Method for developing natural killer cells from stem cells
WO2014165707A2 (en) 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
WO2016123100A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
JP6773268B2 (ja) * 2015-03-09 2020-10-21 学校法人慶應義塾 多能性幹細胞を所望の細胞型へ分化する方法
CN105517672B (zh) * 2015-05-26 2019-06-21 中国科学院广州生物医药与健康研究院 一种人原代细胞培养基及其应用
PL412787A1 (pl) * 2015-06-22 2017-01-02 Magdalena Król Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną
CN107850596B (zh) * 2015-07-24 2020-12-04 先天制药公司 用于检测组织浸润nk细胞的方法
ES2922475T3 (es) * 2015-09-08 2022-09-15 Sumitomo Pharma Co Ltd Método para producir células epiteliales pigmentarias de la retina
CN108368520B (zh) 2015-11-04 2023-01-17 菲特治疗公司 多能细胞的基因组工程改造
WO2017078807A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
CN105296428A (zh) * 2015-12-03 2016-02-03 广州医科大学附属第三医院 一种提高诱导多能干细胞的体外分化造血效率的方法
JP2019505498A (ja) 2015-12-16 2019-02-28 ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ Ｎｋ細胞におけるサイトカイン誘導性ｓｈ２タンパク質の阻害
US20190161726A1 (en) * 2016-07-29 2019-05-30 Daikin Industries, Ltd. Differentiated cell production method and culture bag used therefor
US20190194621A1 (en) * 2016-09-08 2019-06-27 Kyowa Hakko Bio Co., Ltd. Medium for culturing stem cells, method for culturing stem cells, growth promoter for stem cells, and cell composition and method for producing same
JP7092281B2 (ja) * 2017-02-07 2022-06-28 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 多能性幹細胞から模倣自然免疫細胞を生成する方法及びキット
US11696927B2 (en) * 2017-02-28 2023-07-11 University Of Central Florida Research Foundation, Inc. PM21 particles to improve bone marrow homing of NK cells
CN110573610B (zh) 2017-03-08 2025-01-28 住友制药株式会社 视网膜色素上皮细胞的制备方法
US20200080058A1 (en) * 2017-03-21 2020-03-12 Etablissement Francais Du Sang Methods of improving hematopoietic grafts
KR102167548B1 (ko) * 2017-09-21 2020-10-19 한국생명공학연구원 자연살해세포의 제조방법 및 그의 용도
JP7433230B2 (ja) 2017-12-08 2024-02-19 ジュノー セラピューティクス インコーポレイテッド 細胞を培養するための無血清培地配合物およびその使用の方法
AU2019215034C1 (en) 2018-02-01 2022-01-06 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
FI3755347T3 (fi) * 2018-02-21 2025-07-29 Univ Texas Universaaleja antigeeniä esitteleviä soluja ja niiden käyttöjä
SG11202101204TA (en) 2018-08-09 2021-03-30 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
WO2020037303A1 (en) 2018-08-16 2020-02-20 The Regents Of The University Of California Chemically and photochemically initiated cell membrane blebbing to induce cell vesicle production, modifications thereof, and uses thereof
RS65658B1 (sr) 2018-08-27 2024-07-31 Affimed Gmbh Kriokonzervirane nk ćelije prethodno punjene konstruktom antitela
AU2019336221B2 (en) 2018-09-07 2025-05-15 Wisconsin Alumni Research Foundation Generation of hematopoietic progenitor cells from human pluripotent stem cells
WO2020180744A1 (en) * 2019-03-01 2020-09-10 The Regents Of The University Of California Natural killer cell induced cellular vesicles for cancer therapy
KR102298639B1 (ko) * 2019-03-28 2021-09-07 한국생명공학연구원 면역세포의 제조방법 및 그의 용도
RU2731293C1 (ru) 2019-04-12 2020-09-01 Игорь Петрович Белецкий Способ получения генно-модифицированных линий клеток натуральных киллеров с нокаутированным геном PD-1 и повышенной экспрессией белков семейства Фактора Некроза Опухолей для иммунотерапии онкологических заболеваний
US20220154144A1 (en) * 2019-04-26 2022-05-19 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial antigen presenting cells comprising ligands for nkg2d for expanding immune cells for immunotherapy
WO2021096218A1 (ko) 2019-11-13 2021-05-20 연세대학교 산학협력단 혈관 내피세포 순수 분리 방법, 혈관 내피세포 특성 유지 배지 및 이를 포함하는 배양 방법
CN111235105B (zh) * 2020-03-06 2021-08-10 安徽中盛溯源生物科技有限公司 一种从人多能干细胞分化为自然杀伤细胞的方法及应用
CN116018148A (zh) * 2020-03-11 2023-04-25 全国儿童医院研究所 Nk细胞及其用于治疗微生物感染的用途
US11547726B2 (en) 2020-03-26 2023-01-10 Honed Life Sciences, Llc Enhancement of production of NK cells from stem cells
EP4170020A4 (en) 2020-06-17 2025-01-22 Kyoto University IMMUNOCOMPETENT CELLS WITH CHIMERIC ANTIGEN RECEPTOR EXPRESSION
AU2021317752A1 (en) * 2020-07-27 2023-03-02 Stemcell Technologies Canada Inc. Systems and methods for differentiating hematopoietic cells
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
CN112608895B (zh) * 2020-12-18 2024-02-27 深圳市济因生物科技有限公司 一种人多能干细胞分化的自然杀伤细胞及其制备方法与应用
US11473060B2 (en) 2020-12-30 2022-10-18 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into NK cells
EP4326852A4 (en) * 2021-04-22 2025-04-23 Artec Biotech, Inc. Method for producing hematopoietic cells from stem cells using vascular organoids
WO2022269393A1 (en) 2021-06-23 2022-12-29 Crispr Therapeutics Ag Engineered cells with improved protection from natural killer cell killing
CN115261318B (zh) * 2021-09-29 2024-05-28 苏州艾凯利元生物科技有限公司 产生自然杀伤细胞的方法
US20250000974A1 (en) * 2021-10-27 2025-01-02 The Regents Of The University Of California Combination of human natural killer cells and macrophages for cancer therapy
CN113957048A (zh) * 2021-10-29 2022-01-21 深圳市默赛尔生物医学科技发展有限公司 一种利用脐带血单个核细胞生产自然杀伤细胞的方法
JP2025500894A (ja) 2021-12-17 2025-01-15 ウモジャ バイオファーマ インコーポレイテッド 細胞傷害性自然リンパ球系細胞およびその使用
US20250122474A1 (en) * 2022-01-31 2025-04-17 Healios K.K. Production method for natural killer cells
CN114507641B (zh) * 2022-04-20 2022-07-12 山东兴瑞生物科技有限公司 一种由人胚胎干细胞诱导分化为nk细胞的方法
WO2023233342A2 (en) 2022-06-01 2023-12-07 Crispr Therapeutics Ag Gene-edited natural killer cells
AU2023285113A1 (en) * 2022-06-09 2024-12-12 Umoja Biopharma, Inc. Compositions and methods for nk cell differentiation
CN115058387B (zh) * 2022-06-11 2023-12-01 重庆医科大学 一种人胚胎干细胞与前列腺癌细胞共培养制备抗前列腺癌药物的方法
EP4562133A1 (en) * 2022-07-27 2025-06-04 Umoja Biopharma, Inc. Differentiation of stem cells in suspension culture
WO2024101862A1 (ko) * 2022-11-07 2024-05-16 마루테라퓨틱스 주식회사 Nk 세포의 분화 효율 및 기능성 증가를 위한 배양 방법
WO2024101863A1 (ko) * 2022-11-07 2024-05-16 마루테라퓨틱스 주식회사 줄기세포 기원 및 발현 마커에 따른 nk 세포 분화 효율 증진 방법
KR20240069648A (ko) * 2022-11-10 2024-05-20 의료법인 성광의료재단 전분화능 줄기세포에서 자연살해세포로의 분화 유도용 배지 조성물 및 이를 이용한 분화 방법
WO2024224359A1 (en) * 2023-04-27 2024-10-31 Takeda Pharmaceutical Company Limited Method for expanding cd56+/cd3- cells

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0018737B1 (en) 1979-04-11 1983-11-09 Mitsui Petrochemical Industries, Ltd. Process for producing spherical carrier particles for olefin polymerisation catalyst, catalyst comprising such carrier particles, and use of such catalyst in olefin polymerisation
EP0187371B1 (en) 1984-12-27 1991-06-19 Asahi Kasei Kogyo Kabushiki Kaisha Substituted isoquinolinesulfonyl compounds
US6355476B1 (en) 1988-11-07 2002-03-12 Advanced Research And Technologyinc Nucleic acid encoding MIP-1α Lymphokine
EP0814838B1 (en) 1995-03-08 2003-05-14 The Scripps Research Institute Antigen presenting system and activation of t-cells
AU723355B2 (en) 1996-05-23 2000-08-24 Scripps Research Institute, The MHC class II antigen presenting systems and methods for activating CD4+ T cells
AU5734998A (en) 1997-01-10 1998-08-03 Life Technologies, Inc. Embryonic stem cell serum replacement
US6790662B1 (en) 1999-03-12 2004-09-14 Ortho-Mcneil Pharmaceutical, Inc. Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides
US6844354B1 (en) 1999-03-25 2005-01-18 Mitsubishi Pharma Corporation Agent for prophylaxis and treatment of interstitial pneumonia and pulmonary fibrosis
AU5250400A (en) 1999-06-18 2001-01-09 Mitsubishi Pharma Corporation Osteogenesis promoters
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
MXPA04007196A (es) 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
US6664266B2 (en) 2002-03-14 2003-12-16 Children's Medical Center Corporation Axon regeneration with PKC inhibitiors
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
US7393835B2 (en) 2002-04-22 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase C
BRPI0514778B1 (pt) 2004-09-08 2018-07-10 Wisconsin Alumni Research Foundation Meio para cultivar células tronco embrionárias
US7993638B2 (en) 2006-03-01 2011-08-09 Janssen Pharmaceutica Nv Cancer treatment combining lymphodepleting agent with CTLs and cytokines
CA2665568C (en) 2006-10-04 2018-01-09 Janssen Pharmaceutica, N.V. Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
US8513012B2 (en) 2008-05-02 2013-08-20 Cellular Dynamics International, Inc. Method for production of mast cells from stem cells
CN102388130B (zh) 2009-02-27 2014-08-27 细胞动力国际有限公司 多能细胞的分化
BR112012014104A2 (pt) * 2009-12-04 2016-07-05 Stem Cell & Regenerative Medicine International Inc método de geração de células destrutoras naturais e células dendríticas de hemangioblastos embrionários humanos derivados de células-tronco
US9260696B2 (en) * 2012-04-24 2016-02-16 Dan S. Kaufman Method for developing natural killer cells from stem cells

Also Published As

Publication number Publication date
AU2013251785B2 (en) 2018-05-10
JP2017158590A (ja) 2017-09-14
WO2013163171A1 (en) 2013-10-31
US20130287751A1 (en) 2013-10-31
JP2015519890A (ja) 2015-07-16
JP2019122415A (ja) 2019-07-25
AU2020264375A1 (en) 2020-12-03
EP2841563A1 (en) 2015-03-04
EP2841563B1 (en) 2019-06-12
US9260696B2 (en) 2016-02-16
AU2020264375B2 (en) 2023-05-25
AU2013251785A1 (en) 2014-09-18
EP3567102A1 (en) 2019-11-13
AU2018206749A1 (en) 2018-08-09
JP6529541B2 (ja) 2019-06-12

Similar Documents

Publication Publication Date Title
AU2020264375B2 (en) Method for developing natural killer cells from stem cells
JP7138134B2 (ja) 血管コロニー形成細胞および非生着血管細胞
US9988602B2 (en) Methods for producing enucleated erythroid cells derived from pluripotent stem cells
JP5630781B2 (ja) 血管コロニー形成細胞
HK40017506A (en) Method for developing natural killer cells from stem cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170613

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180123

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180511

R150 Certificate of patent or registration of utility model

Ref document number: 6339998

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250